TABLE 1.
Characteristics of lung transplant recipients who received at least one dose of recombinant zoster vaccine
| Characteristics | N = 49 |
|---|---|
| Age (years) [median (IQR)] | 65.4 (59.1–70.6) |
| Male (%) | 29 (59.2) |
| Time from transplant to first vaccine (years) [median (IQR)] | 3.0 (1.0–5.0) |
| Within first year of transplantation (%) | 12 (24.5) |
| Double lung transplant (%) | 40 (81.6) |
| Previous live attenuated herpes zoster vaccinea (%) | 12 (24.5) |
| Previous herpes zoster episodea (%) | 7 (14.3) |
| Underlying lung disease (%) | |
| Idiopathic pulmonary fibrosis | 21 (42.6) |
| COPD | 11 (22.4) |
| Cystic Fibrosis | 2 (4.1) |
| Other | 15 (30.6) |
| Antithymocyte globulin 3–6 months prior (%) | 2 (4.1) |
| Basiliximab 3–6 months prior (%) | 3 (6.1) |
| Immunosuppression | |
| Prednisone (%) | 49 (100.0) |
| Prednisone dose (mg/day) [median (IQR)] | 10 (5–10) |
| Tacrolimus (%) | 16 (33.3) |
| Tacrolimus trough level (ng/ml) [median (IQR)] | 12.5 (7.2–14.9) |
| Cyclosporin (%) | 33 (66.6) |
| Cyclosporin trough level (ng/ml) [median (IQR)] | 192 (155–227) |
| Mycophenolate mofetil / Mycophenolate sodium (%) | 41 (83.7) |
| Azathioprine (%) | 7 (14.3) |
Data apply to all patients who received at least one dose of herpes zoster subunit vaccine.
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
a
Based on self-report at time of enrollment.